| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 58 | 2024 | 1114 | 13.850 |
Why?
|
| Lung Neoplasms | 83 | 2024 | 2347 | 12.950 |
Why?
|
| Pneumonectomy | 25 | 2024 | 206 | 6.450 |
Why?
|
| Neoplasm Staging | 41 | 2024 | 2001 | 3.610 |
Why?
|
| Thoracic Surgery | 8 | 2022 | 44 | 3.120 |
Why?
|
| Neoadjuvant Therapy | 9 | 2024 | 373 | 2.270 |
Why?
|
| Surgeons | 6 | 2022 | 247 | 2.010 |
Why?
|
| Osteopontin | 6 | 2013 | 47 | 1.920 |
Why?
|
| Thoracic Surgical Procedures | 5 | 2024 | 55 | 1.740 |
Why?
|
| Radiosurgery | 9 | 2021 | 280 | 1.700 |
Why?
|
| Physicians, Women | 5 | 2022 | 56 | 1.560 |
Why?
|
| Humans | 138 | 2024 | 89063 | 1.520 |
Why?
|
| Specialties, Surgical | 2 | 2021 | 65 | 1.400 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2023 | 1363 | 1.360 |
Why?
|
| Early Detection of Cancer | 5 | 2024 | 415 | 1.340 |
Why?
|
| Thoracic Surgery, Video-Assisted | 6 | 2022 | 30 | 1.340 |
Why?
|
| Mesothelioma | 14 | 2023 | 323 | 1.260 |
Why?
|
| Adenocarcinoma | 11 | 2016 | 1194 | 1.240 |
Why?
|
| Pleural Neoplasms | 11 | 2016 | 198 | 1.130 |
Why?
|
| Small Cell Lung Carcinoma | 4 | 2023 | 103 | 1.090 |
Why?
|
| Esophagectomy | 5 | 2009 | 92 | 1.050 |
Why?
|
| Disease Management | 3 | 2019 | 329 | 0.870 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2022 | 485 | 0.850 |
Why?
|
| Catheter Ablation | 6 | 2015 | 252 | 0.840 |
Why?
|
| Thymectomy | 1 | 2022 | 31 | 0.840 |
Why?
|
| Jehovah's Witnesses | 1 | 2022 | 20 | 0.840 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2020 | 2657 | 0.820 |
Why?
|
| Immunotherapy | 6 | 2023 | 669 | 0.810 |
Why?
|
| Radium | 4 | 2023 | 7 | 0.800 |
Why?
|
| Myasthenia Gravis | 1 | 2022 | 83 | 0.800 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 1543 | 0.770 |
Why?
|
| Symptom Assessment | 1 | 2020 | 66 | 0.720 |
Why?
|
| United States | 18 | 2024 | 6955 | 0.720 |
Why?
|
| Treatment Outcome | 15 | 2024 | 8203 | 0.710 |
Why?
|
| Antibody Formation | 1 | 2020 | 171 | 0.710 |
Why?
|
| Societies, Medical | 4 | 2024 | 570 | 0.710 |
Why?
|
| Esophageal Neoplasms | 4 | 2009 | 332 | 0.700 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 309 | 0.690 |
Why?
|
| Combined Modality Therapy | 11 | 2022 | 1710 | 0.680 |
Why?
|
| Female | 50 | 2024 | 46011 | 0.680 |
Why?
|
| Surgical Flaps | 3 | 2017 | 249 | 0.670 |
Why?
|
| Aged | 32 | 2024 | 19077 | 0.660 |
Why?
|
| Mass Screening | 3 | 2022 | 636 | 0.660 |
Why?
|
| Male | 45 | 2024 | 42251 | 0.650 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2016 | 1096 | 0.640 |
Why?
|
| Robotic Surgical Procedures | 2 | 2022 | 304 | 0.630 |
Why?
|
| SEER Program | 4 | 2024 | 197 | 0.620 |
Why?
|
| Middle Aged | 36 | 2024 | 25863 | 0.620 |
Why?
|
| Neoplasms, Second Primary | 5 | 2016 | 260 | 0.610 |
Why?
|
| Retrospective Studies | 16 | 2024 | 9003 | 0.570 |
Why?
|
| Probability | 1 | 2017 | 353 | 0.560 |
Why?
|
| Salvage Therapy | 2 | 2017 | 235 | 0.560 |
Why?
|
| Skin Ulcer | 1 | 2016 | 25 | 0.560 |
Why?
|
| Hyaluronan Receptors | 2 | 2013 | 38 | 0.530 |
Why?
|
| Frozen Sections | 1 | 2015 | 49 | 0.520 |
Why?
|
| Skin Transplantation | 1 | 2016 | 183 | 0.510 |
Why?
|
| Prognosis | 16 | 2021 | 3773 | 0.510 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 6777 | 0.500 |
Why?
|
| Monitoring, Intraoperative | 1 | 2015 | 110 | 0.500 |
Why?
|
| Esophagus | 2 | 2006 | 106 | 0.490 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2012 | 142 | 0.460 |
Why?
|
| Pancoast Syndrome | 1 | 2013 | 2 | 0.460 |
Why?
|
| Survival Rate | 10 | 2024 | 1889 | 0.460 |
Why?
|
| Radiopharmaceuticals | 3 | 2012 | 193 | 0.460 |
Why?
|
| Fas Ligand Protein | 1 | 2013 | 49 | 0.430 |
Why?
|
| Adult | 28 | 2024 | 26507 | 0.430 |
Why?
|
| Positron-Emission Tomography | 5 | 2013 | 336 | 0.420 |
Why?
|
| Fluorine Radioisotopes | 1 | 2012 | 25 | 0.400 |
Why?
|
| Radiation Injuries | 2 | 2010 | 160 | 0.400 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 99 | 0.400 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 579 | 0.390 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 111 | 0.380 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 232 | 0.380 |
Why?
|
| Bronchogenic Cyst | 1 | 2010 | 5 | 0.380 |
Why?
|
| Thoracic Diseases | 1 | 2010 | 27 | 0.370 |
Why?
|
| Soft Tissue Infections | 1 | 2010 | 26 | 0.370 |
Why?
|
| Thoracic Wall | 1 | 2010 | 25 | 0.360 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 1149 | 0.360 |
Why?
|
| Risk Assessment | 7 | 2022 | 2290 | 0.350 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 461 | 0.340 |
Why?
|
| Survival Analysis | 4 | 2019 | 1533 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 2552 | 0.340 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2022 | 296 | 0.340 |
Why?
|
| Simulation Training | 2 | 2021 | 97 | 0.340 |
Why?
|
| Education, Medical, Graduate | 3 | 2020 | 390 | 0.330 |
Why?
|
| Lung Transplantation | 2 | 2024 | 290 | 0.330 |
Why?
|
| Health Status Disparities | 1 | 2011 | 187 | 0.320 |
Why?
|
| Perfusion | 3 | 2024 | 235 | 0.310 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 540 | 0.310 |
Why?
|
| Consensus | 4 | 2024 | 356 | 0.280 |
Why?
|
| Dumping Syndrome | 1 | 2006 | 5 | 0.270 |
Why?
|
| Gastric Emptying | 1 | 2006 | 25 | 0.270 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 410 | 0.260 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 604 | 0.260 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2411 | 0.260 |
Why?
|
| Stomach | 1 | 2006 | 111 | 0.250 |
Why?
|
| Esophageal Diseases | 1 | 2005 | 27 | 0.250 |
Why?
|
| Patient Selection | 3 | 2020 | 682 | 0.250 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 319 | 0.250 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 304 | 0.250 |
Why?
|
| Transcription Factors | 1 | 2013 | 1652 | 0.250 |
Why?
|
| Patient Care Management | 2 | 2020 | 30 | 0.240 |
Why?
|
| Lung | 5 | 2024 | 1258 | 0.240 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2006 | 111 | 0.240 |
Why?
|
| Intubation, Intratracheal | 1 | 2006 | 148 | 0.240 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 119 | 0.240 |
Why?
|
| Computer Simulation | 3 | 2021 | 1097 | 0.240 |
Why?
|
| Chemoradiotherapy | 3 | 2024 | 309 | 0.240 |
Why?
|
| General Surgery | 1 | 2007 | 235 | 0.240 |
Why?
|
| Risk Factors | 5 | 2022 | 5466 | 0.230 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 3657 | 0.230 |
Why?
|
| Gastroesophageal Reflux | 1 | 2006 | 122 | 0.230 |
Why?
|
| Postoperative Complications | 4 | 2024 | 2275 | 0.230 |
Why?
|
| Smoking | 2 | 2024 | 620 | 0.220 |
Why?
|
| Thymoma | 1 | 2023 | 30 | 0.220 |
Why?
|
| Hamartoma | 1 | 2003 | 34 | 0.220 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 120 | 0.220 |
Why?
|
| Negative-Pressure Wound Therapy | 2 | 2014 | 10 | 0.220 |
Why?
|
| Thymus Neoplasms | 1 | 2023 | 43 | 0.220 |
Why?
|
| Lymphatic Metastasis | 4 | 2010 | 502 | 0.220 |
Why?
|
| Radiotherapy, Conformal | 1 | 2023 | 84 | 0.210 |
Why?
|
| Medical Oncology | 1 | 2007 | 382 | 0.210 |
Why?
|
| Frailty | 1 | 2024 | 76 | 0.210 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2002 | 30 | 0.210 |
Why?
|
| Chylothorax | 1 | 2022 | 10 | 0.210 |
Why?
|
| Chylous Ascites | 1 | 2022 | 9 | 0.210 |
Why?
|
| Time Factors | 4 | 2023 | 5320 | 0.200 |
Why?
|
| Health Care Costs | 1 | 2023 | 235 | 0.200 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 1108 | 0.200 |
Why?
|
| ErbB Receptors | 2 | 2022 | 500 | 0.190 |
Why?
|
| Steroids | 1 | 2022 | 174 | 0.190 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 46 | 0.190 |
Why?
|
| Funnel Chest | 1 | 2021 | 8 | 0.190 |
Why?
|
| Pneumothorax | 2 | 2020 | 53 | 0.190 |
Why?
|
| Lung Diseases | 1 | 2003 | 269 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 112 | 0.190 |
Why?
|
| Cohort Studies | 6 | 2024 | 2863 | 0.190 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 43 | 0.190 |
Why?
|
| Immunization, Passive | 1 | 2020 | 71 | 0.180 |
Why?
|
| Betacoronavirus | 2 | 2020 | 261 | 0.180 |
Why?
|
| Critical Pathways | 1 | 2020 | 37 | 0.180 |
Why?
|
| Pandemics | 3 | 2021 | 771 | 0.180 |
Why?
|
| Case-Control Studies | 4 | 2013 | 1855 | 0.170 |
Why?
|
| Sexual Harassment | 1 | 2019 | 9 | 0.170 |
Why?
|
| Career Choice | 1 | 2021 | 148 | 0.170 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 280 | 0.170 |
Why?
|
| Protein Isoforms | 2 | 2010 | 274 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 833 | 0.160 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2018 | 10 | 0.160 |
Why?
|
| Sexism | 1 | 2019 | 53 | 0.160 |
Why?
|
| Drainage | 1 | 2020 | 162 | 0.160 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 27 | 0.160 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 463 | 0.160 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 1591 | 0.150 |
Why?
|
| Thoracotomy | 1 | 2018 | 64 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 168 | 0.150 |
Why?
|
| Respiratory System | 1 | 2018 | 116 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 616 | 0.150 |
Why?
|
| Safety-net Providers | 1 | 2018 | 37 | 0.150 |
Why?
|
| Wound Closure Techniques | 1 | 2017 | 15 | 0.150 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 23 | 0.150 |
Why?
|
| Thoracic Neoplasms | 1 | 2017 | 64 | 0.140 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 433 | 0.140 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 60 | 0.140 |
Why?
|
| Lymph Nodes | 2 | 2011 | 548 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 4 | 2016 | 86 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1650 | 0.130 |
Why?
|
| Asbestos | 2 | 2012 | 22 | 0.130 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 73 | 0.130 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 142 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 305 | 0.130 |
Why?
|
| Apoptosis | 2 | 2013 | 1716 | 0.130 |
Why?
|
| Biopsy | 2 | 2016 | 1182 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 201 | 0.120 |
Why?
|
| Subcutaneous Emphysema | 1 | 2014 | 8 | 0.120 |
Why?
|
| Photochemotherapy | 1 | 1995 | 100 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 887 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1177 | 0.120 |
Why?
|
| Simian virus 40 | 4 | 1998 | 35 | 0.120 |
Why?
|
| Area Under Curve | 2 | 2012 | 337 | 0.120 |
Why?
|
| Prospective Studies | 6 | 2023 | 4273 | 0.120 |
Why?
|
| Radiography | 2 | 2014 | 809 | 0.120 |
Why?
|
| Receptor, EphB2 | 1 | 2013 | 3 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 576 | 0.110 |
Why?
|
| Peritoneum | 1 | 2013 | 57 | 0.110 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 46 | 0.110 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 181 | 0.110 |
Why?
|
| Operative Time | 1 | 2013 | 142 | 0.110 |
Why?
|
| Microbiota | 1 | 2018 | 398 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2013 | 157 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2612 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2013 | 794 | 0.110 |
Why?
|
| Organ Preservation | 2 | 2024 | 105 | 0.110 |
Why?
|
| ROC Curve | 2 | 2012 | 781 | 0.110 |
Why?
|
| Epithelium | 1 | 2013 | 325 | 0.100 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 112 | 0.100 |
Why?
|
| Pain Management | 1 | 2013 | 137 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2012 | 127 | 0.100 |
Why?
|
| Cytokines | 3 | 2022 | 802 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2007 | 172 | 0.100 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2013 | 139 | 0.100 |
Why?
|
| Biomarkers | 2 | 2016 | 1755 | 0.100 |
Why?
|
| Job Satisfaction | 1 | 2012 | 76 | 0.100 |
Why?
|
| Occupational Exposure | 1 | 2012 | 87 | 0.100 |
Why?
|
| Palliative Care | 1 | 2013 | 263 | 0.100 |
Why?
|
| Young Adult | 5 | 2021 | 6288 | 0.100 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2011 | 25 | 0.100 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 39 | 0.090 |
Why?
|
| Sternoclavicular Joint | 1 | 2010 | 2 | 0.090 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2010 | 8 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 40 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1400 | 0.090 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 40 | 0.090 |
Why?
|
| Ribonucleases | 1 | 2011 | 93 | 0.090 |
Why?
|
| Cell Movement | 2 | 2013 | 783 | 0.090 |
Why?
|
| Debridement | 1 | 2010 | 57 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 695 | 0.090 |
Why?
|
| Computer-Assisted Instruction | 1 | 2011 | 44 | 0.090 |
Why?
|
| Models, Anatomic | 1 | 2011 | 91 | 0.090 |
Why?
|
| Functional Laterality | 1 | 2011 | 200 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2009 | 1057 | 0.090 |
Why?
|
| Mutation | 1 | 2022 | 4132 | 0.090 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 106 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2011 | 2552 | 0.090 |
Why?
|
| Joint Diseases | 1 | 2010 | 48 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2011 | 308 | 0.090 |
Why?
|
| Necrosis | 1 | 2010 | 209 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2010 | 96 | 0.090 |
Why?
|
| Tracheal Neoplasms | 1 | 2009 | 8 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2019 | 1041 | 0.090 |
Why?
|
| Pain, Postoperative | 1 | 2012 | 251 | 0.090 |
Why?
|
| Glomus Tumor | 1 | 2009 | 9 | 0.090 |
Why?
|
| Chest Pain | 1 | 2009 | 42 | 0.080 |
Why?
|
| Sarcoidosis | 1 | 2010 | 72 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2010 | 426 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2012 | 185 | 0.080 |
Why?
|
| Endosonography | 1 | 2010 | 98 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2010 | 121 | 0.080 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 251 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 374 | 0.080 |
Why?
|
| Mediastinal Neoplasms | 2 | 2005 | 47 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2013 | 2011 | 0.080 |
Why?
|
| MicroRNAs | 2 | 2011 | 551 | 0.080 |
Why?
|
| Length of Stay | 2 | 2020 | 732 | 0.080 |
Why?
|
| Wound Healing | 1 | 2010 | 359 | 0.080 |
Why?
|
| Microwaves | 1 | 2008 | 36 | 0.080 |
Why?
|
| Radiation Oncologists | 2 | 2018 | 14 | 0.080 |
Why?
|
| Chest Tubes | 2 | 2020 | 24 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 442 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 421 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2011 | 465 | 0.070 |
Why?
|
| DNA, Viral | 2 | 1998 | 261 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 1063 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 2 | 1998 | 45 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 364 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 1429 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 479 | 0.070 |
Why?
|
| Pulmonary Ventilation | 1 | 2006 | 33 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1214 | 0.070 |
Why?
|
| Sialoglycoproteins | 1 | 2006 | 31 | 0.070 |
Why?
|
| Cognition | 1 | 2011 | 580 | 0.070 |
Why?
|
| Carbonic Anhydrases | 1 | 2006 | 15 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2006 | 171 | 0.070 |
Why?
|
| Mediastinoscopy | 1 | 2005 | 5 | 0.070 |
Why?
|
| History, 21st Century | 2 | 2017 | 180 | 0.060 |
Why?
|
| California | 1 | 2006 | 144 | 0.060 |
Why?
|
| Thoracic Injuries | 1 | 2006 | 38 | 0.060 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 9 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 2 | 1998 | 184 | 0.060 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 470 | 0.060 |
Why?
|
| Esophagoplasty | 1 | 2005 | 10 | 0.060 |
Why?
|
| Anesthetics | 1 | 2005 | 53 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2005 | 115 | 0.060 |
Why?
|
| Risk | 1 | 2006 | 657 | 0.060 |
Why?
|
| Eligibility Determination | 1 | 2024 | 36 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 332 | 0.060 |
Why?
|
| Frail Elderly | 1 | 2024 | 82 | 0.060 |
Why?
|
| Incidence | 2 | 2022 | 1592 | 0.060 |
Why?
|
| Adolescent | 3 | 2021 | 9237 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2024 | 229 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2024 | 126 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 84 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 396 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2022 | 23 | 0.050 |
Why?
|
| Work-Life Balance | 1 | 2022 | 6 | 0.050 |
Why?
|
| Asthma | 1 | 2009 | 976 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 313 | 0.050 |
Why?
|
| Transfection | 3 | 2011 | 911 | 0.050 |
Why?
|
| Leukocytes | 1 | 2022 | 204 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2003 | 386 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 109 | 0.050 |
Why?
|
| Oxygen | 1 | 2006 | 742 | 0.050 |
Why?
|
| Clinical Competence | 2 | 2020 | 780 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 145 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1043 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 66 | 0.050 |
Why?
|
| Epitopes | 1 | 2021 | 255 | 0.040 |
Why?
|
| Bioethics | 1 | 2020 | 35 | 0.040 |
Why?
|
| Risk Management | 1 | 2020 | 42 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 198 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 131 | 0.040 |
Why?
|
| Child | 2 | 2022 | 7149 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 39 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 481 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 233 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 261 | 0.040 |
Why?
|
| Asbestosis | 2 | 1998 | 5 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 130 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 423 | 0.040 |
Why?
|
| Living Donors | 1 | 2022 | 339 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 120 | 0.040 |
Why?
|
| Sputum | 1 | 2018 | 35 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2022 | 490 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 126 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2021 | 493 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 1998 | 81 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1998 | 68 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 295 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1998 | 153 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 248 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 761 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 573 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 865 | 0.040 |
Why?
|
| Liver | 1 | 2022 | 1205 | 0.040 |
Why?
|
| RNA, Antisense | 1 | 1996 | 15 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 164 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 2014 | 0.030 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 1996 | 18 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 1996 | 779 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 948 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2018 | 307 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 200 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 738 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 245 | 0.030 |
Why?
|
| Anniversaries and Special Events | 1 | 2016 | 14 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1662 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2021 | 779 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 1998 | 261 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 1995 | 115 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2017 | 121 | 0.030 |
Why?
|
| Base Sequence | 2 | 1996 | 2327 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1995 | 159 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1995 | 172 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1995 | 125 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1995 | 155 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 310 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2335 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 665 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3027 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 1995 | 390 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2018 | 537 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1796 | 0.030 |
Why?
|
| DNA Damage | 1 | 1995 | 371 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 306 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 323 | 0.030 |
Why?
|
| Cricetinae | 3 | 1998 | 558 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 1995 | 370 | 0.030 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2012 | 16 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2012 | 47 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1996 | 699 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 1995 | 490 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 282 | 0.030 |
Why?
|
| Fear | 1 | 2012 | 79 | 0.020 |
Why?
|
| Self Concept | 1 | 2012 | 132 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 557 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1140 | 0.020 |
Why?
|
| Thoracoscopes | 1 | 2011 | 2 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 321 | 0.020 |
Why?
|
| Surgical Staplers | 1 | 2011 | 11 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 130 | 0.020 |
Why?
|
| Dissection | 1 | 2011 | 44 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2011 | 100 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2010 | 36 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 304 | 0.020 |
Why?
|
| Motor Skills | 1 | 2011 | 79 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2011 | 65 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 859 | 0.020 |
Why?
|
| Mediastinum | 1 | 2010 | 47 | 0.020 |
Why?
|
| Affect | 1 | 2012 | 387 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 988 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 233 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 519 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1067 | 0.020 |
Why?
|
| Empyema | 1 | 2008 | 9 | 0.020 |
Why?
|
| Depression | 1 | 2012 | 503 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2880 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2006 | 1265 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 1998 | 114 | 0.020 |
Why?
|
| Plasmids | 2 | 1998 | 291 | 0.020 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2006 | 11 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2006 | 20 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 590 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1867 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 2005 | 36 | 0.020 |
Why?
|
| Tracheal Diseases | 1 | 2005 | 14 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 921 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1715 | 0.020 |
Why?
|
| Animals | 4 | 1998 | 27317 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2752 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 261 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 1488 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1998 | 91 | 0.010 |
Why?
|
| Virus Replication | 1 | 1998 | 321 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 1998 | 115 | 0.010 |
Why?
|
| Oxygenators | 1 | 1996 | 3 | 0.010 |
Why?
|
| Sarcoma, Ewing | 1 | 1996 | 44 | 0.010 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 1996 | 31 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1996 | 156 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1996 | 73 | 0.010 |
Why?
|
| Safety | 1 | 1996 | 149 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1998 | 447 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 696 | 0.010 |
Why?
|
| Sarcoma | 1 | 1996 | 220 | 0.010 |
Why?
|
| Remission Induction | 1 | 1996 | 740 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1996 | 451 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1996 | 319 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1996 | 899 | 0.010 |
Why?
|
| Melanoma | 1 | 1996 | 467 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1996 | 435 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 1157 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 4040 | 0.010 |
Why?
|